ONC vs SYK
BeOne Medicines AG vs Stryker Corporation — AI-powered side-by-side comparison
ONC
BeOne Medicines AG
67
Buy
VS
SYK
Stryker Corporation
59
Buy
| Metric | ONC | SYK |
|---|
| AI Score |
67
|
59
|
| Price |
$374.44
|
$329.92
|
| P/E Ratio |
27.73×
|
33.98×
|
| ROE |
6.6%
|
14.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
87.8%
|
65.2%
|
| Debt / Equity |
0.22×
|
0.62×
|
| Dividend Yield |
0.0%
|
1.1%
|
| RSI (14) |
70.6
|
44.6
|
| Beta |
0.5
|
0.771
|
| Expected Upside |
+2.1%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for ONC versus SYK.
ONC leads by 8 points.
ONC scores 67/100 (Buy) versus SYK at 59/100 (Buy).
ONC Committee View
83% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+1.00 across 1 articles, 14d). Value Analyst remains cautious — p/e of 88.1 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 36.2% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 88.1 is expensive by classic value standards — Value
- Price-to-book of 8.7x prices in significant intangible value — Value
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
SYK Committee View
60% agreement
5 analysts
Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 27.7% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 35.2 is moderate-to-rich — Value
- Price-to-book of 6.0x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical